Evidence map›Paper›PMID 37271281›Full record

ReviewNeuropharmacology2023

Cell-type specific molecular architecture for mu opioid receptor function in pain and addiction circuits.

Nicole E Ochandarena, Jesse K Niehaus, Adrien Tassou, Grégory Scherrer

Open access · greenAbstract readReview
In one paragraph

Review in Neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicole E OchandarenaNeuroscience Curriculum, Biological and Biomedical Sciences Program, The University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA; Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; UNC Neuroscience Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: nicole_ochandarena@med.unc.edu.
Jesse K NiehausDepartment of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; UNC Neuroscience Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Adrien TassouDepartment of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; UNC Neuroscience Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Grégory ScherrerDepartment of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; UNC Neuroscience Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; New York Stem Cell Foundation - Robertson Investigator, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: gregory_scherrer@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

A comprehensive dissection of cell types, circuits and molecular adaptations during opioid useR01DA054583 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHERRER, GREGORY, SCHNITZER, MARK J · 2021 to 2025
$7.0M
Targeting GPCRs in amygdalar and cortical neural ensembles to treat pain aversionR01NS118504 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHERRER, GREGORY · 2020 to 2024
$3.5M
Identification of cells and signaling mechanisms underlying opioid analgesia and side effectsR01DA044481 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHERRER, GREGORY · 2017 to 2021
$1.8M
Molecular profiling of medullary descending pain modulation circuits to discover novel analgesic targetsR21DA049241 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHERRER, GREGORY · 2019 to 2021
$428k
Characterizing the connectivity and molecular composition of opioid-sensitive neurons in the periaqueductal grayF32DA057779 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NIEHAUS, JESSE · 2023 to 2025
$226k
Circuit mechanisms for opioid analgesia and addiction in prefrontal cortexF30DA057839 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI OCHANDARENA, NICOLE ELISE · 2023 to 2025
$132k
NIDA NIH HHS F30 DA057839NIDA NIH HHS F32 DA057779NIDA NIH HHS R01 DA044481NIDA NIH HHS R01 DA054583NIDA NIH HHS R21 DA049241NINDS NIH HHS R01 NS118504
6 · The paper itself

Abstract

Opioids are potent analgesics broadly used for pain management; however, they can produce dangerous side effects including addiction and respiratory depression. These harmful effects have led to an epidemic of opioid abuse and overdose deaths, creating an urgent need for the development of both safer pain medications and treatments for opioid use disorders. Both the analgesic and addictive properties of opioids are mediated by the mu opioid receptor (MOR), making resolution of the cell types and neural circuits responsible for each of the effects of opioids a critical research goal. Single-cell RNA sequencing (scRNA-seq) technology is enabling the identification of MOR-expressing cell types throughout the nervous system, creating new opportunities for mapping distinct opioid effects onto newly discovered cell types. Here, we describe molecularly defined MOR-expressing neuronal cell types throughout the peripheral and central nervous systems and their potential contributions to opioid analgesia and addiction.

Indexed as

Analgesics, OpioidOpioid-Related DisordersAnalgesicsHumansPainReceptors, Opioid, muAnalgesicsAnalgesics, OpioidReceptors, Opioid, muCell typesMu opioid receptorNervous systemOpioid addictionOpioid analgesiaSingle cell RNA-Sequencing

Identifiers

PMID37271281
PMCPMC10494323
OpenAlexW4379208037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.